GlassScriptPhysician profile
Allene Fonseca
NPI 1487008025
$5,421.57
in general payments reported to CMS, 2019-2025
25 companies · $2,627 in 2025
The $2,627 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $359 · 2023: $1,014 · 2024: $1,421 · 2025: $2,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764 · Travel and Lodging: $1,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,764.28 |
| Travel and Lodging | $1,298.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,044.27 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $708.46 | 2022-2025 | Libtayo, Dupixent |
| Genzyme Corporation | $662.79 | 2024-2025 | |
| Dermavant Sciences, INC. | $240.80 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $218.15 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.80 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $138.60 | 2025 | Nemluvio |
| Mallinckrodt Hospital Products INC. | $125.73 | 2023 | Uvadex |
| Glaxosmithkline, LLC. | $121.90 | 2022 | |
| Ucb, INC. | $120.33 | 2024-2025 | Bimzelx |
| Krystal Biotech INC | $119.70 | 2025 | Vyjuvek |
| Organon LLC | $116.48 | 2025 | Vtama |
| Pfizer INC. | $112.65 | 2024 | |
| Biofrontera INC. | $76.66 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sun Pharmaceutical Industries INC. | $74.90 | 2023-2024 | Ilumya |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72.75 | 2023-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $63.55 | 2022-2024 | Valchlor |
| E.R. Squibb & Sons, L.L.C. | $34.47 | 2023 | Sotyktu |
| Leo Pharma INC. | $28.80 | 2025 | Adbry |
| Incyte Corporation | $27.68 | 2024 | Opzelura |
| Janssen Scientific Affairs, LLC | $27.15 | 2024 | Tremfya |
| 180 Medical, INC. | $21.99 | 2024 | |
| Fresenius Kabi USA, LLC | $19.18 | 2023 | |
| Lilly USA, LLC | $17.86 | 2024 | Taltz, Olumiant |
| Amgen INC. | $13.92 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allene Fonseca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.